SMARTSTRUCTURESProject reference: 297929
Funded under :
Synthesis of Smart Virus-like Hierarchical Structures Based-on Polymer-Peptide Conjugates and the Potential Application in Drug Delivery
Total cost:EUR 209 033,4
EU contribution:EUR 209 033,4
Coordinated in:United Kingdom
Topic(s):FP7-PEOPLE-2011-IEF - Marie-Curie Action: "Intra-European fellowships for career development"
Call for proposal:FP7-PEOPLE-2011-IEFSee other projects for this call
Funding scheme:MC-IEF - Intra-European Fellowships (IEF)
"In this proposal, we intend to combine the advantages of virus and polymersome structural motifs into one integrated model as a promising strategy to construct hybrid structures that are efficient delivery vehicles. First, folic acid-modified polyN-(2-hydroxypropyl)methacrylamide-poly(L-cysteine) conjugate (FA-PHPMA-b-PLC) will be synthesized. The biocompatible PHPMA is used as the hydrophilic part, and PLC is chosen for its ability to aggregate in water (by either hydrogen or covalent bonding via beta-sheet formation or disulphide linkage). Not only do the thiol groups in PLC chain play an important role for covalent loading of drugs/proteins/genes via thiol exchange with disulfide groups, but also the oxidation of the cysteine residues to form intra- and intermolecular disulfide bridges further stabilize the polymersome structure. After forming the polymersome, the biomolecules will be incorporated by either covalent or noncovalent mechanisms. Finally, zinc oxide nanoparticles modified by disulfide-linked pyridine will be covalently encapsulated into the PLC shell to obtain the hybrid virus-like structure with ZnO nanoparticles as a key component of the coronal layer. We anticipate that the constructed hybrid structure will enter the target cell by endocytosis. The low pH in the endosome (pH~5) will then accelerate the dissolution of the ZnO nanoparticles and release the biomolecules. Subsequently, glutathione in the cytoplasm will reduce the cross-linked disulfides in PLC shell and lead to the disassembly of the polymersome. Therefore, as a new hybrid structure that integrates significant advantages of both the polymersome and virus models of biomolecule delivery, it is reasonable to believe that it will provide a new advance for the design of delivery vehicles for the cure of cancer-related diseases."
EU contribution: EUR 209 033,4
TYNDALL AVENUE SENATE HOUSE
BS8 1TH BRISTOL
Tel.: +44 117 3317371